Certara (NASDAQ:CERT) Price Target Raised to $13.00
Robert W. Baird raised Certara's price target from $9.00 to $13.00, maintaining a "neutral" rating. This suggests a potential upside of 23.69% from the current price. Other analysts have varying ratings, with a consensus rating of "Moderate Buy" and an average target price of $15.50. Certara's stock opened at $10.51, with a 52-week range of $8.64 to $18.68. Institutional investors hold 73.96% of the stock, indicating strong interest in the company.
Certara (NASDAQ:CERT - Get Free Report) had its target price boosted by research analysts at Robert W. Baird from $9.00 to $13.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Robert W. Baird's price objective suggests a potential upside of 23.69% from the company's current price.
- Simulations Plus Stock Drops 15% Despite EPS Beat
CERT has been the topic of several other reports. Stephens reiterated an "overweight" rating and set a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. TD Cowen began coverage on shares of Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 price target on the stock. William Blair restated a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Finally, Barclays reduced their target price on Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a report on Thursday. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $15.50.
View Our Latest Analysis on CERT
Certara Stock Performance
- Are These 3 Small Momentum Stocks Setting Up Big Gains?
Certara stock opened at $10.51 on Friday. The stock has a fifty day moving average price of $11.63 and a 200 day moving average price of $11.35. Certara has a 52 week low of $8.64 and a 52 week high of $18.68. The firm has a market capitalization of $1.69 billion, a P/E ratio of -52.55, a PEG ratio of 9.29 and a beta of 1.64. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.
Hedge Funds Weigh In On Certara
Several hedge funds and other institutional investors have recently made changes to their positions in CERT. Versant Capital Management Inc increased its holdings in Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after purchasing an additional 1,866 shares in the last quarter. Venturi Wealth Management LLC boosted its position in shares of Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after buying an additional 2,509 shares during the period. Wells Fargo & Company MN grew its stake in shares of Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after buying an additional 1,047 shares in the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Certara during the 4th quarter valued at about $47,000. Finally, Blue Trust Inc. lifted its position in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after acquiring an additional 822 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.
About Certara
(Get Free Report)- Certara Stock is Key Biosimulation Play
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Further Reading
- Five stocks we like better than Certara
- What Investors Need to Know About Upcoming IPOs
- IAMGOLD Stock Climbs as Turnaround Story Gains Traction
- Profitably Trade Stocks at 52-Week Highs
- 3 Energy Stock Winners Even as Oil Prices Plunge
- Insider Trading - What You Need to Know
- Micron Tumbles on Tariff Threat: Risk/Reward Outlook Improves
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Certara Right Now?
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
